

Effective **August 1, 2021**, the Alberta Biosimilars Initiative will be updated with the following changes that will affect adult members on Alberta government-sponsored drug plans.

**Addition of insulin lispro biosimilar – all adult patients on Humalog must switch by February 1, 2022**

**1. Update to Alberta Drug Benefit List (ADBL)**

On August 1, 2021, a new insulin lispro biosimilar drug, Admelog, was listed on the Alberta Drug Benefit List (ADBL) and will be subject to the Alberta Biosimilar Initiative.

**2. Coverage**

Effective August 1, 2021, all new insulin lispro starts are covered with a biosimilar version of insulin lispro. Adult patients currently taking Humalog will be required to switch to a biosimilar version by February 1, 2022 to maintain coverage for this molecule through their Alberta government-sponsored drug plan.

Please note: patients that require access to the originator biologic drug because their insulin pump has not yet been approved for use with the biosimilar should have their physician submit an exception request. Patients enrolled in the Alberta Insulin Pump Therapy Program (IPTP) and using a Medtronic insulin pump do not need to submit an exception request as an exemption will be in place until the biosimilar is approved for use.